戻る Agenda
Orphan Drug Development Strategy by Big and Medium/Small Pharmaceutical Industries
Session Chair(s)
Noriaki Murao, DIAFellow, MS
Senior Consultant (Pharmaceuticals)
NM Consulting, Japan
This session will address considerations for planning the development and commercialization strategy of orphan drugs by large as well as small companies.
Learning Objective : Discuss an overview of the development of orphan drug strategies in large and small pharmaceutical companies; Describe considerations on planning and commercialization strategies of orphan drugs.
Speaker(s)
Perspective on Orphan Drug Development: From the Industry Viewpoint
Yoshihiko Ono, RPH
MSD K.K., Japan
Regulatory Executive Advisor
Evolution of a Biotech from Startup to Mid Cap: Making the Orphan Disease Strategy Happen
Kenneth N. Hitchner, MA
BioMarin Pharmaceutical Inc., United States
Vice President, Development Sciences Project Management
Value and Specificity of Rare Diseases Business Model: Is the Pursuit of This Societal Priority Sustainable?
Michael C. Diem, MD
GlaxoSmithKline, United States
Director and Head of Business Development, GSK Rare Diseases